Assessment of Quality of Life in Patients with Head and Neck Cancer
Authors:
M. Švajdová 1,2; D. Ondruš 2
Authors place of work:
Klinika radiačnej a klinickej onkológie ÚVN Ružomberok – FN, Ružomberok
1; I. onkologická klinika LF UK a OÚSA, Bratislava
2
Published in the journal:
Klin Onkol 2020; 33(3): 195-200
Category:
Přehled
doi:
https://doi.org/10.14735/amko2020195
Summary
Background: With the improvement of the results of oncological treatment, the concept of Quality of Life (QoL) has become increasingly important. Quantitative expression of the length of survival does not provide complete information on all advantages and disadvantages of the applied treatment. Hence, natural societal inquiry arises to answer the question what is QoL that such treatment option brings to the patient. With equivalent effi cacy of diff erent treatment modalities, the expected QoL after treatment might be the most important factor infl uencing the patient‘s decision for a particular type of treatment. Questionnaires are the basic tools on quantifying QoL. Over the last decades, the development of questionnaire tools has undergone a signifi cant process of evolution and nowadays, many diff erent validated measures are available to assess the physical, functional, emotional, and social impact of cancer and its treatment on patient’s life. In head and neck cancer treatment, the assessment of QoL outcomes is especially important for patients and healthcare workers because of the potential negative impact of the treatment on important functions such as speech, swallowing, communication and social relationships.
Purpose: The purpose of this article is to provide an up-to-date overview of validated questionnaire tools used in clinical practice with emphasis on potential future improvement in their design and clinical utility. The article defi nes the concept of QoL itself and currently available forms of its evaluation. Furthermore, the types of individual questionnaire tools are discussed within the text with practical and clearly arranged examples of world-famous validated scales evaluating specifi c items that represent the focus of research interest.
Keywords:
Quality of life – head and neck cancer – health-related quality of life – Questionnaires
Zdroje
1. La Vecchia C, Bosetti C, Lucchini F et al. Cancer mortality in Europe. 2000–2004 and an overview of trends since 1975. Ann Oncol 2010; 21(6): 1323–1361. doi: 10.1093/ annonc/ mdp530
2. Kaušitz J, Ondruš D et al. Špeciálna onkológia. Bratislava: Solen 2020.
3. Dušek L et al. Czech Cancer Care in Numbers. 2008– 2009. Praha: Grada Publishing 2009.
4. WHO QOL Measuring Quality of Life, 1999. [online]. Available from: https://www.who.int/healthinfo/survey/ whoqol-qualityofl ife/en/.
5. Calvert M, Blateby J, Altman DG et al. Reporting of patient-reported outcomes in randomized trials. The Consort pro extension. JAMA 2013; 309(8): 814–822. doi: 10.1001/ jama.2013.879.
6. Chandu A, Smith AC, Rogers SN. Health-related quality of life in oral cancer: a review. J Oral Maxillofac Surg 2006; 64(3): 495–502. doi: 10.1016/ j.joms.2005.11.028.
7. Calman KC. Quality of life in cancer patients – a hypothesis. J Med Ethics 1984; 10(3): 124 –127. doi: 10.1136/ jme.10.3.124.
8. Rogers SN, Ahad SA, Murphy AP. A structured review and theme analysis of papers published on ‘quality of life’ in head and neck cancer: 2000–2005. Oral Oncol 2007; 43(9): 843–868. doi: 10.1016/ j.oraloncology.2007.02. 006.
9. Ringash J, Bezjak A. A structured review of quality of life instruments for head and neck cancer patients. Head Neck 2001; 23(3): 201–213. doi: 10.1002/ 1097-0347(200103)23:3.
10. Sayed S, Elmiyeh B, Rhys-Evans P et al. Quality of life and outcomes research in head and neck cancer: a review of the state of the discipline and likely future directions. Cancer Treat Rev 2009; 35(5): 397–402. doi: 10.1016/ j.ctrv.2009.03.001.
11. Karnofsky D, Burchenal JH. The clinical evaluation of chemotherapeutic agents against cancer. New York (NY): Columbia University Press 1949.
12. Questionnaire European Organisation for Research and Treatment of Cancer (EORTC). [online]. Available from: http:/ / www. groups.eortc.be/ qol/.
13. Questionnaires. [online]. Available from: http:/ / www. facit.org/ FACITOrg/ Questionnaires.
14. Merseyside Regional Head & Neck Cancer. [online]. Available from: http:/ / www.headandneckcancer.co.uk.
15. Luckett T, King MT, Butow PN et al. Choosing between the EORTC QLQ-C30 and FACT-G for measuring health-related quality of life in cancer clinical research: issues, evidence and recommendations. Ann Oncol 2011; 22(10): 20179–2190. doi: 10.1093/ annonc/ mdq721.
16. Thomas L, Jones TM, Tandon S et al. Speech and voice outcomes in oropharyngeal cancer and evaluation of theUniversity of Washington Quality of Life speech domain. Clin Otolaryngol 2009; 34(1): 34–42. doi: 10.1111/ j.1749- 4486.2008.01830.x.
17. Terrell JE, Ronis DL, Fowler KE et al. Clinical predictors of quality of life in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 2004; 130(4): 401–408. doi: 10.1001/ archotol.130.4.401.
18. Post-operative Adjuvant Treatment for HPV-positive tumours (PATHOS). [online]. Available from: https:/ / clinicaltrials.gov/ ct2/ show/ NCT02215265.
19. Pusic A, Liu JC, Chen CM et al. A systematic review of patient-reported outcome measures in head and neck cancer surgery. Otolaryngol Head Neck Surg 2007; 136(4): 525–535. doi: 10.1016/ j.otohns.2006.12.006.
20. Kanatas AN, Rogers SN. A guide of the questionnaires used in the measurement of health-related quality of life in head and neck oncology. Tumori 2008; 94(5): 724–731.
21. Heutte N, Plisson L, Lange M et al. Quality of life tools in head and neck oncology. Eur Ann Otorhinolaryngol Head Neck Dis 2014; 131(1): 33–47. doi: 10.1016/ j. anorl.2013.05.002.
22. Djan R, Penington A. A systematic review of questionnaires to measure the impact of appearance on quality of life for head and neck cancer patients. J Plast Reconstr Aesthet Surg 2013; 66(5): 647–659. doi: 10.1016/ j. bjps.2013.01.007.
23. University of Washington Quality of Life Questionnaire (UW-QOL v4). [online]. Available from: http:/ / www. headandneck cancer.co.uk/ For+professionals/ Quality+of+Life+(QOL)/ UW-QOLv4+Translations.aspx.
24. Patient Concerns Inventory. [online]. Available from: http:/ / www.patient-concerns-inventory.co.uk/ translations.html.
25. Process of translation and adaptation of instruments. [online]. Available from: http:/ / www.who.int/ substance_abuse/ research_tools/ translation/ en/ .
26. Singer S, Araújo C, Arraras JI et al. Measuring quality of life in patients with head and neck cancer: Update of the EORTC QLQ-H&N module, phase III. Head Neck 2015; 37(9): 1358–1367. doi: 10.1002/ hed.23762.
27. Chera BS, Eisbruch A, Murphy BA et al. Recommended patient-reported core set of symptoms to measure in head and neck cancer treatment trials. J Natl Cancer Inst 2014; 106(7): dju127. doi: 10.1093/ jnci/ dju127.
28. Vissers PA, Thong MS, Pouwer F et al. The impact of comorbidity on Health-Related Quality of Life among cancer survivors: analyses of data from the PROFILES registry. J Cancer Surviv 2013; 7(4): 602–613. doi: 10.1007/ s11764- 013-0299-1.
29. Rogers SN, Hogg ES, Cheung WK et al. ‘What will I be like’ after my dia gnosis of head and neck cancer? Eur Arch Otorhinolaryngol 2015; 272(9): 2463–2472. doi: 10.1007/ s00405-014-3189-x.
30. HaNDLE-on-QoL. Head and neck database listing evidence on QoL. [online]. Available from: http:/ / www.handle-on-qol.com/ Index.aspx.
31. Rogers SN. Improving quality-of-life questionnaires in head and neck cancer. [online]. Available from: https:/ / www.tandfonline.com/ doi/ full/ 10.1080/ 2380900 0.2016.1142357.
Štítky
Dětská onkologie Chirurgie všeobecná OnkologieČlánek vyšel v časopise
Klinická onkologie
2020 Číslo 3
- Metamizol jako analgetikum první volby: kdy, pro koho, jak a proč?
- Management pacientů s MPN a neobvyklou kombinací genových přestaveb – systematický přehled a kazuistiky
- Management péče o pacientku s karcinomem ovaria a neočekávanou mutací CDH1 – kazuistika
- Neodolpasse je bezpečný přípravek v krátkodobé léčbě bolesti
- Cinitaprid – v Česku nová účinná látka nejen pro léčbu dysmotilitní dyspepsie
Nejčtenější v tomto čísle
- Hladiny NT-proBNP a troponínu T u onkologických pacientov – stručný prehľad
- Kompletná odpoveď na chemoterapiu pri metastatickom karcinóme pankreasu spojenom s dvojitou heterozygotnou zárodočnou mutáciou génov BRCA2 a CHEK2 – kazuistika
- Význam aberantně aktivované dráhy Hedgehog/Gli pro nádorovou progresi
- Hodnotenie kvality života u pacientov s nádormi hlavy a krku